LCI News and Press, Lannett Co Inc From 02/22/22

Lannett finds itself at a confluence of choices brought forth more by management than the macro-environment. With revenues sinking to new lows, investors are left wondering if management can find a path to the aspirational goal of $1 billion in revenues by 2025. With a share price...

Gainers: TDCX (NYSE:TDCX) +16%. ALJ Regional Holdings (NASDAQ:ALJJ) +8%. Nxt-ID (NASDAQ:NXTD) +8%. Microvast Holdings (NASDAQ:MVST) +7%. Archer Aviation (NYSE:ACHR) +7%. Losers: SkyWest (NASDAQ:SKYW) -21%. GrafTech International (NYSE:EAF) -9%. Alpine 4 Holdings (NASDAQ:AL...

Gainers: Snap (NYSE:SNAP) +52%. Bill.com Holdings (NYSE:BILL) +31%. Indonesia Energy Corporation (NYSE:INDO) +28%. eGain (NASDAQ:EGAN) +22%. Sphere (NASDAQ:ANY) +21%. Standard Lithium (NYSE:SLI) +17%. Aurora Innovation (NASDAQ:AUR) +17%. Unity Software (NYSE:U) +17%. Astria Therapeutics (NASD...

Lannett (LCI -27.5%) stock plummeted Feb. 4, after its Q2 results failed to beat analysts' estimates and a revised fiscal 2022 outlook. Q2 net sales declined to $86.5M, compared to $133.9M in Q2 fiscal 2021. "For the quarter, ongoing and increasing competitive pricing pressure across our...

Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...

Lannett Company, Inc. (LCI) Q2 2022 Earnings Conference Call February 03, 2022 4:30 PM ET Company Participants Robert Jaffe – Investor Relations Tim Crew – Chief Executive Officer John Kozlowski – Chief Financial Officer Conference Call Participants Scott Henry – R...

Lannett press release (NYSE:LCI): Q2 Non-GAAP EPS of -$0.39 misses by $0.07. Revenue of $86.5M (-35.4% Y/Y) misses by $3.71M. Shares -16%. Adj. 2022 Guidance:  Net sales: $335 million to $360 million, down from $370 million to $400 million vs. $389.69M consensus. Gross margin&#...

LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE -- Q2 Business and Financial Highlights: - Net Sales were $86.5 Million - Negative Adjusted EBITDA was $1.0 Million - Cash in Excess of $98 Million at December 31 - Nove...

LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3 PR Newswire TREVOSE, Pa. , Jan. 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for ...

LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE --FDA States Pivotal Clinical Trial May Proceed, Trial Expected to Commence By March 2022-- PR Newswire PHILADELPHIA , Jan. 21, 2022 /PRNewswi...